Dexcom (DXCM) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
15 Oct, 2026Executive summary
Q4 revenue was $1.035B, up 26% organically and 27% reported YoY; FY2023 revenue was $3.622B, up 24%.
Expanded access, record new customer starts and global G7 rollout supported momentum; management expected continued growth in 2024.
Financial highlights
Q4 GAAP net income was $256.3M and diluted EPS was $0.62, vs. $91.8M and $0.22 YoY; non-GAAP net income was $202.8M and diluted EPS was $0.50.
Q4 GAAP operating income was $216.9M vs. $125.4M; non-GAAP operating income was $242.7M vs. $172.1M YoY.
FY2023 GAAP operating income was $597.7M vs. $391.2M; GAAP net income was $541.5M vs. $341.2M.
Nearly 500 bps of operating expense leverage was generated vs. Q4 2022.
Outlook and guidance
FY2024 revenue guidance: $4.15B–$4.35B, representing 16%–21% organic growth; non-GAAP gross margin 63%–64%, non-GAAP operating margin ~20% and adjusted EBITDA margin ~29%.
Guidance factors include G6-to-G7 conversion, launches for type 2 basal and non-insulin hypoglycemia populations, Dexcom ONE expansion and YoY operating expense leverage.
Organic growth excludes FX and non-CGM revenue acquired or divested in the trailing 12 months; guidance assumes divestiture of non-CGM assets that contributed ~$30M of FY2023 revenue.
Latest events from Dexcom
- Revenue growth and margin gains were offset by lower earnings and a major Verily charge.DXCM
Q4 2021 - Revenue grew 19% as G7 clearance and expanded CGM access strengthened growth prospects.DXCM
Q4 2022 - Revenue climbed 43% as profitability arrived and G6 capacity doubled.DXCM
Q4 2019 - 31% revenue growth and 66% gross margin, with earnings lifted by a major tax benefit.DXCM
Q4 2020 - G6-led revenue topped $1B as launch investment and the Verily charge widened losses.DXCM
Q4 2018 - Q3 revenue and margins grew, lifting FY2026 guidance and supporting a new $1B buyback.DXCM
Q3 2026 - CONNECT data, expanded coverage, and product innovation set stage for accelerated growth.DXCM
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue rose 13%, net income 39%, margins and guidance up, $600M shares repurchased.DXCM
Q2 2026 - Q3 2024 saw 2–3% revenue growth, strong international gains, and a $750M share repurchase.DXCM
Q3 2024